Compare Glenmark Pharma with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs SUN PHARMA - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA SUN PHARMA GLENMARK PHARMA/
SUN PHARMA
 
P/E (TTM) x 14.9 456.1 3.3% View Chart
P/BV x 2.4 2.8 86.7% View Chart
Dividend Yield % 0.4 0.6 72.6%  

Financials

 GLENMARK PHARMA   SUN PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
SUN PHARMA
Mar-19
GLENMARK PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs712679 104.8%   
Low Rs484375 128.8%   
Sales per share (Unadj.) Rs349.6121.1 288.6%  
Earnings per share (Unadj.) Rs32.813.4 245.1%  
Cash flow per share (Unadj.) Rs44.320.7 214.3%  
Dividends per share (Unadj.) Rs2.002.75 72.7%  
Dividend yield (eoy) %0.30.5 64.1%  
Book value per share (Unadj.) Rs198.6172.6 115.1%  
Shares outstanding (eoy) m282.172,399.26 11.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.74.4 39.3%   
Avg P/E ratio x18.239.4 46.3%  
P/CF ratio (eoy) x13.525.5 52.9%  
Price / Book Value ratio x3.03.1 98.5%  
Dividend payout %6.120.6 29.7%   
Avg Mkt Cap Rs m168,6251,264,650 13.3%   
No. of employees `00012.017.5 68.8%   
Total wages/salary Rs m20,56159,671 34.5%   
Avg. sales/employee Rs Th8,196.016,608.1 49.3%   
Avg. wages/employee Rs Th1,708.13,409.6 50.1%   
Avg. net profit/employee Rs Th768.51,833.8 41.9%   
INCOME DATA
Net Sales Rs m98,655290,659 33.9%  
Other income Rs m2,08110,255 20.3%   
Total revenues Rs m100,736300,914 33.5%   
Gross profit Rs m15,85863,076 25.1%  
Depreciation Rs m3,25917,533 18.6%   
Interest Rs m3,3465,553 60.3%   
Profit before tax Rs m11,33550,246 22.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,672-12,144 -13.8%   
Tax Rs m3,7566,009 62.5%   
Profit after tax Rs m9,25032,093 28.8%  
Gross profit margin %16.121.7 74.1%  
Effective tax rate %33.112.0 277.1%   
Net profit margin %9.411.0 84.9%  
BALANCE SHEET DATA
Current assets Rs m66,968310,692 21.6%   
Current liabilities Rs m40,211173,396 23.2%   
Net working cap to sales %27.147.2 57.4%  
Current ratio x1.71.8 92.9%  
Inventory Days Days8399 84.1%  
Debtors Days Days81112 72.8%  
Net fixed assets Rs m33,322232,477 14.3%   
Share capital Rs m2822,399 11.8%   
"Free" reserves Rs m55,770411,691 13.5%   
Net worth Rs m56,052414,091 13.5%   
Long term debt Rs m35,73815,226 234.7%   
Total assets Rs m132,888646,938 20.5%  
Interest coverage x4.410.0 43.7%   
Debt to equity ratio x0.60 1,734.0%  
Sales to assets ratio x0.70.4 165.2%   
Return on assets %9.55.8 162.9%  
Return on equity %16.57.8 212.9%  
Return on capital %17.810.2 175.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,99866,025 95.4%   
Fx outflow Rs m22,85938,610 59.2%   
Net fx Rs m40,14027,415 146.4%   
CASH FLOW
From Operations Rs m13,24221,965 60.3%  
From Investments Rs m-6,990-6,813 102.6%  
From Financial Activity Rs m-7,387-27,305 27.1%  
Net Cashflow Rs m-2,971-8,442 35.2%  

Share Holding

Indian Promoters % 48.3 63.7 75.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 5.1 134.5%  
FIIs % 34.4 23.0 149.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 8.3 126.5%  
Shareholders   56,727 133,026 42.6%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  CADILA HEALTHCARE  SUVEN LIFESCIENCES  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 127 Points Higher; Auto Stocks Witness Huge Buying(Closing)

Share markets in India continued to trade on a positive note during closing hours today and ended their session marginally higher.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

My View on ITC(Fast Profits Daily)

Oct 23, 2020

What do the charts say about ITC?

The 'Seedhi Baat, No Bakwaas' View on ITC(Profit Hunter)

Oct 12, 2020

Is ITC an investment or a speculation at current levels?

One of the Best Investment Opportunities in the Market Right Now(Fast Profits Daily)

Oct 16, 2020

The one sector that you should be looking at to make good profits.

Why India's Drone Revolution is a 4x Profit Opportunity(Profit Hunter)

Oct 16, 2020

My research on India's leading defence companies brought me to one major player in drone manufacturing.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Oct 23, 2020 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS